Skip to main content
Top
Published in: Molecular Cancer 1/2021

Open Access 01-12-2021 | Colorectal Cancer | Research

A novel NF-κB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation

Authors: Zhen-xing Liang, Hua-shan Liu, Li Xiong, Xin Yang, Feng-wei Wang, Zi-wei Zeng, Xiao-wen He, Xian-rui Wu, Ping Lan

Published in: Molecular Cancer | Issue 1/2021

Login to get access

Abstract

Background

Constitutive activation of nuclear factor-κB (NF-κB) signaling plays a key role in the development and progression of colorectal carcinoma (CRC). However, the underlying mechanisms of excessive activation of NF-κB signaling remain largely unknown.

Methods

We used high throughput RNA sequencing to identify differentially expressed circular RNAs (circRNAs) between normal human intestinal epithelial cell lines and CRC cell lines. The identification of protein encoded by circPLCE1 was performed using LC–MS. The function of novel protein was validated in vitro and in vivo by gain or loss of function assays. Mechanistic results were concluded by immunoprecipitation analyses.

Results

A novel protein circPLCE1-411 encoded by circular RNA circPLCE1 was identified as a crucial player in the NF-κB activation of CRC. Mechanistically, circPLCE1-411 promoted the ubiquitin-dependent degradation of the critical NF-κB regulator RPS3 via directly binding the HSP90α/RPS3 complex to facilitate the dissociation of RPS3 from the complex, thereby reducing NF-κB nuclear translocation in CRC cells. Functionally, circPLCE1 inhibited tumor proliferation and metastasis in CRC cells, as well as patient-derived xenograft and orthotopic xenograft tumor models. Clinically, circPLCE1 was downregulated in CRC tissues and correlated with advanced clinical stages and poor survival.

Conclusions

circPLCE1 presents an epigenetic mechanism which disrupts NF-κB nuclear translocation and serves as a novel and promising therapeutic target and prognostic marker.
Appendix
Available only for authorised users
Literature
7.
go back to reference Kojima M, et al. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res. 2004;24:675–81.PubMed Kojima M, et al. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res. 2004;24:675–81.PubMed
Metadata
Title
A novel NF-κB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation
Authors
Zhen-xing Liang
Hua-shan Liu
Li Xiong
Xin Yang
Feng-wei Wang
Zi-wei Zeng
Xiao-wen He
Xian-rui Wu
Ping Lan
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2021
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-021-01404-9

Other articles of this Issue 1/2021

Molecular Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine